Novo Nordisk CEO says experimental weight loss pill could become a best in class drug

Novo Nordisk CEO says experimental weight loss pill could become a best in class drug


Novo Nordisk CEO on latest trials, U.S. obesity and demand outlook

Novo Nordisk CEO Lars Fruergaard Jørgensen on Friday said the company’s experimental weight loss pill, amycretin, could eventually become a best-in-class treatment for obesity. 

The Danish drugmaker is racing to capitalize on the runaway success of its blockbuster weight loss drug Wegovy by developing a new generation of treatments for obesity, including more convenient and potentially cheaper pills. 

His remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin. Patients on the pill lost around 13.1% of their weight after 12 weeks, Jørgensen said on CNBC’s “Money Movers.” 

That surpasses the 6% weight loss seen in those who took Wegovy after the same time period. It also adds to the growing enthusiasm around the potential of weight loss pills. 

Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk, speaks during an interview in New York, US, on Wednesday, Aug. 10, 2022. Two more factories will begin producing Novo Nordisk A/S’s obesity medication Wegovy next year after manufacturing issues and high demand left the drug in short supply, Jorgensen said.

Christopher Goodney | Bloomberg | Getty Images

Along with convenience for patients, pills could help alleviate some of the supply constraints plaguing weight loss injections. Wegovy, along with similar drugs, have soared in demand and slipped into intermittent shortages over the last year due to their ability to help patients shed significant weight over time. 

“We believe in the future there’ll be different segments of anti-obesity treatments, with different patients having different preferences,” Jørgensen told CNBC. “Some will prefer an injectable and we really believe that once we can take a pill, it’s a very convenient offering.”

But those pills won’t join the market anytime soon. A mid-stage trial on amycretin will begin in the second half of this year, with results expected in early 2026, the company said on Thursday. 

In a separate interview with Reuters on Friday, Novo Nordisk’s head of development Martin Holst Lange said the company is comfortable in being able to launch amycretin this decade.

Amycretin suppresses appetite by targeting the same gut hormone that Wegovy mimics, which is known as GLP-1. But amycretin also targets a pancreas hormone called amylin, which affects hunger.

U.S.-traded shares of Novo Nordisk rose as much as 8.3% on Thursday after the company released the data, extending the past year’s 68% gain. But the company’s stock fell 2% on Friday. 



Source

UnitedHealth says it is cooperating with DOJ investigation into Medicare billing practices
Health

UnitedHealth says it is cooperating with DOJ investigation into Medicare billing practices

The UnitedHealth logo on a laptop arranged in New York, US, on Friday, July 7, 2023. Gabby Jones | Bloomberg | Getty Images UnitedHealth Group revealed Thursday it is facing a Justice Department investigation over its Medicare billing practices, adding to a string of setbacks for a company that owns the nation’s largest and most […]

Read More
Healthy Returns: Researchers move closer to a universal cancer vaccine
Health

Healthy Returns: Researchers move closer to a universal cancer vaccine

Wildpixel | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A universal cancer vaccine – what once seemed like a pipe dream – may be inching closer to becoming reality.  On […]

Read More
U.S. to remove mercury preservative from flu shots following RFK Jr. vaccine panel vote 
Health

U.S. to remove mercury preservative from flu shots following RFK Jr. vaccine panel vote 

U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., speaks with Agriculture Secretary Brooke Rollins and Senator Roger Marshall (R-KS) ahead of a roundtable event as part of the “Make America Healthy Again” (MAHA) agenda, on Capitol Hill in Washington, D.C., U.S., July 15, 2025. Ken Cedeno | Reuters The Department of Health […]

Read More